{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:18:00Z","timestamp":1790741880338,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,9,24]],"date-time":"2016-09-24T00:00:00Z","timestamp":1474675200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s40257-016-0220-6","type":"journal-article","created":{"date-parts":[[2016,9,24]],"date-time":"2016-09-24T05:08:35Z","timestamp":1474693715000},"page":"545-552","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Adalimumab: A Review in Hidradenitis Suppurativa"],"prefix":"10.1007","volume":"17","author":[{"given":"Esther S.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karly P.","family":"Garnock-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan J.","family":"Keam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,24]]},"reference":[{"key":"220_CR1","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/978-3-662-45139-7_42","volume-title":"European handbook of dermatological treatments","author":"C Dessinioti","year":"2015","unstructured":"Dessinioti C, Zouboulis C. Hidradenitis suppurativa. In: Katsambas AD, Lotti TM, Dessinioti C, et al., editors. European handbook of dermatological treatments. 3rd ed. Berlin: Springer-Verlag; 2015. p. 411\u201322.","edition":"3"},{"key":"220_CR2","doi-asserted-by":"crossref","first-page":"f2121","DOI":"10.1136\/bmj.f2121","volume":"346","author":"F Collier","year":"2013","unstructured":"Collier F, Smith RC, Morton CA. Diagnosis and management of hidradenitis suppurativa. BMJ. 2013;346:f2121.","journal-title":"BMJ."},{"issue":"4","key":"220_CR3","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jdv.12966","volume":"29","author":"CC Zouboulis","year":"2015","unstructured":"Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619\u201344.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"90","key":"220_CR4","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1136\/postgradmedj-2013-131994","volume":"1062","author":"DN Dufour","year":"2014","unstructured":"Dufour DN, Emtestam L, Jemec GB. Hidradenitis suppurativa: a common and burdensome, yet under-recognised, inflammatory skin disease. Postgrad Med J. 2014;1062(90):216\u201321.","journal-title":"Postgrad Med J."},{"issue":"3","key":"220_CR5","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2340\/00015555-1082","volume":"91","author":"S Esmann","year":"2011","unstructured":"Esmann S, Jemec GB. Psychosocial impact of hidradenitis suppurativa: a qualitative study. Acta Derm Venereol. 2011;91(3):328\u201332.","journal-title":"Acta Derm Venereol."},{"issue":"5","key":"220_CR6","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/bjd.14024","volume":"173","author":"T Tzellos","year":"2015","unstructured":"Tzellos T, Zouboulis CC, Gulliver W, et al. Cardiovascular disease risk factors in patients with hidradenitis suppurativa: a systematic review and meta-analysis of observational studies. Br J Dermatol. 2015;173(5):1142\u201355.","journal-title":"Br J Dermatol."},{"issue":"6","key":"220_CR7","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2340\/00015555-0749","volume":"89","author":"L Matusiak","year":"2009","unstructured":"Matusiak L, Bieniek A, Szepietowski JC. Increased serum tumour necrosis factor-alpha in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-alpha agents? Acta Derm Venereol. 2009;89(6):601\u20133.","journal-title":"Acta Derm Venereol."},{"issue":"6","key":"220_CR8","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/j.1365-2133.2011.10254.x","volume":"164","author":"HH Zee van der","year":"2011","unstructured":"van der Zee HH, de Ruiter L, van den Broecke DG, et al. Elevated levels of tumour necrosis factor (TNF)-\u03b1, interleukin (IL)-1\u03b2 and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-\u03b1 and IL-1\u03b2. Br J Dermatol. 2011;164(6):1292\u20138.","journal-title":"Br J Dermatol."},{"issue":"6","key":"220_CR9","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.jaad.2015.08.052","volume":"73","author":"S Hessam","year":"2015","unstructured":"Hessam S, Sand M, Gambichler T, et al. Correlation of inflammatory serum markers with disease severity in patients with hidradenitis suppurativa (HS). J Am Acad Dermatol. 2015;73(6):998\u20131005.","journal-title":"J Am Acad Dermatol."},{"key":"220_CR10","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/978-3-7091-1241-0_19","volume-title":"Skin necrosis","author":"K Zarchi","year":"2015","unstructured":"Zarchi K, Jemec GBE. Hidradenitis suppurativa. In: T\u00e9ot L, Meaume S, Akita S, et al., editors. Skin necrosis. Vienna: Springer; 2015. p. 131\u20135."},{"key":"220_CR11","unstructured":"AbbVie Ltd. Adalimumab (Humira\u00ae) solution for injection: EU summary of product characteristics. 2016. http:\/\/www.ema.europa.eu . Accessed 23 Aug 2016."},{"key":"220_CR12","unstructured":"AbbVie Inc. Humira\u00ae (adalimumab) injection: US prescribing information. 2016. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/ . Accessed 23 Aug 2016."},{"issue":"18","key":"220_CR13","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1007\/s40265-015-0503-x","volume":"75","author":"CB Burness","year":"2015","unstructured":"Burness CB, McKeage K. Adalimumab: a review in chronic plaque psoriasis. Drugs. 2015;75(18):2119\u201330.","journal-title":"Drugs."},{"issue":"2","key":"220_CR14","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2165\/00063030-200418020-00005","volume":"18","author":"LM Bang","year":"2004","unstructured":"Bang LM, Keating GM. Adalimumab: a review of its use in rheumatoid arthritis. BioDrugs. 2004;18(2):121\u201339.","journal-title":"BioDrugs."},{"issue":"1","key":"220_CR15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2165\/0128071-200910010-00008","volume":"10","author":"KF Croom","year":"2009","unstructured":"Croom KF, McCormack PL. Adalimumab: in plaque psoriasis. Am J Clin Dermatol. 2009;10(1):43\u201350.","journal-title":"Am J Clin Dermatol."},{"key":"220_CR16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/3-7643-7438-1_3","volume-title":"TNF-alpha inhibitors","author":"R Shukla","year":"2006","unstructured":"Shukla R, Vender RB. Pharmacology of TNF inhibitors. In: Weinberg JM, Buchholz R, editors. TNF-alpha inhibitors. Basel: Birkh\u00e4user; 2006. p. 23\u201344."},{"issue":"12","key":"220_CR17","doi-asserted-by":"crossref","first-page":"846","DOI":"10.7326\/0003-4819-157-12-201212180-00004","volume":"157","author":"AB Kimball","year":"2012","unstructured":"Kimball AB, Kerdel F, Adams D, et al. Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med. 2012;157(12):846\u201355.","journal-title":"Ann Intern Med."},{"issue":"2","key":"220_CR18","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1365-2133.2011.10698.x","volume":"166","author":"HH Zee van der","year":"2012","unstructured":"van der Zee HH, Laman JD, de Ruiter L, et al. Adalimumab (antitumour necrosis factor-\u03b1) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study. Br J Dermatol. 2012;166(2):298\u2013305.","journal-title":"Br J Dermatol."},{"key":"220_CR19","unstructured":"Koenig D, Noertersheuser P, Okun M, et al. Pharmacokinetics of adalimumab in adult patients with moderate to severe hidradenitis suppurativa [abstract no. 3079191]. In: 23rd World Congress of Dermatology; 2015."},{"key":"220_CR20","unstructured":"European Medicines Agency. Humira-H-C-481-II-0137: EPAR\u2014assessment report\u2014variation. 2015. http:\/\/www.ema.europa.eu . Accessed 23 Aug 2016."},{"key":"220_CR21","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","volume":"375","author":"AB Kimball","year":"2016","unstructured":"Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375:422\u201334.","journal-title":"N Engl J Med."},{"key":"220_CR22","unstructured":"Armstrong A, Pinsky B, Sundaram M, et al. Adalimumab improves dermatology life quality index in patients with hidradenitis suppurativa: pooled data from PIONEER I and II phase 3 randomized controlled trials [abstract no. P0066]. In: 24th European Academy of Dermatology and Venereology Congress; 2015."},{"key":"220_CR23","unstructured":"Jemec GB, Sundaram M, Pinsky B, et al. Adalimumab improves treatment satisfaction with medication in patients with moderate to severe hidradenitis suppurativa in an integrated analysis from PIONEER I and PIONEER II [abstract no. P0063]. In: 24th European Academy of Dermatology and Venereology Congress; 2015."},{"key":"220_CR24","unstructured":"Kimball A, Jemec G, Armstrong A, et al. Evaluating optimal medium-term dosing strategy for adalimumab in moderate-to-severe hidradenitis suppurativa: integrated results from the PIONEER I & II phase 3, randomized, placebo-controlled trials [abstract no. 3079375 plus poster]. In: 23rd World Congress of Dermatology; 2015."},{"key":"220_CR25","unstructured":"Kimball AB, Tzellos T, Geng Z, et al. Clinical meaningfulness of the hidradenitis suppurativa clinical response endpoint to assess inflammation and treatment response in 2 phase 3, randomized, placebo-controlled trials (PIONEER I and II) [abstract no. P0030]. In: 24th European Academy of Dermatology and Venereology Congress; 2015."},{"key":"220_CR26","unstructured":"Sobell J, Weisman J, Brooks DM, et al. Time to response in patients with moderate-to-severe hidradenitis suppurativa who were treated with adalimumab: results from PIONEER I and PIONEER II [abstract no. P0032]. In: 24th European Academy of Dermatology and Venereology Congress; 2015."},{"issue":"5 Suppl","key":"220_CR27","first-page":"AB75","volume":"74","author":"J Sobell","year":"2016","unstructured":"Sobell J, Brooks DM, Geng Z, et al. Time to response in patients with moderate-to-severe hidradenitis suppurativa who were treated with adalimumab: results from PIONEER I and PIONEER II [abstract no. 3495]. J Am Acad Dermatol. 2016;74(5 Suppl):AB75.","journal-title":"J Am Acad Dermatol."},{"key":"220_CR28","unstructured":"Kimball A, Sundaram M, Chen N, et al. Adalimumab is associated with improvements in overall pain and duration of pain response in patients with moderate to severe hidradenitis suppurativa (HS): results from two clinical trials [abstract no. 2982766]. In: 23rd World Congress of Dermatology; 2015."},{"issue":"6","key":"220_CR29","first-page":"731","volume":"150","author":"M Megna","year":"2015","unstructured":"Megna M, Bettoli V, Chimenti S, et al. Hidradenitis suppurativa: guidelines of the Italian Society of Dermatology and Venereology (SIDeMaST) for the use of anti-TNF-alpha agents. G Ital Dermatol Venereol. 2015;150(6):731\u20139.","journal-title":"G Ital Dermatol Venereol."},{"key":"220_CR30","unstructured":"National Institute for Health and Care Excellence. Adalimumab for treating moderate to severe hidradenitis suppurativa. 2016. https:\/\/www.nice.org.uk . Accessed 23 Aug 2016."},{"key":"220_CR31","unstructured":"AbbVie. Humira\u00ae (adalimumab) approved by European Commission for moderate to severe hidradenitis suppurativa (HS). 2015. http:\/\/abbvie.mediaroom.com\/ . Accessed 23 Aug 2016."},{"key":"220_CR32","unstructured":"AbbVie. Abbvie\u2019s Humira\u00ae (adalimumab) receives first and only U.S. Food and Drug Administration approval for moderate to severe hidradenitis suppurativa. 2015. http:\/\/abbvie.mediaroom.com . Accessed 23 Aug 2016."},{"key":"220_CR33","first-page":"CD010081","volume":"10","author":"JR Ingram","year":"2015","unstructured":"Ingram JR, Woo PN, Chua SL, et al. Interventions for hidradenitis suppurativa. Cochrane Database Syst Rev. 2015;10:CD010081.","journal-title":"Cochrane Database Syst Rev."},{"issue":"1","key":"220_CR34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.det.2015.08.012","volume":"34","author":"DC Rappard van","year":"2016","unstructured":"van Rappard DC, Mekkes JR, Tzellos T. Randomized controlled trials for the treatment of hidradenitis suppurativa. Dermatol Clin. 2016;34(1):69\u201380.","journal-title":"Dermatol Clin."},{"issue":"5 Suppl 1","key":"220_CR35","first-page":"AB208","volume":"72","author":"B Moyano-Almagro","year":"2015","unstructured":"Moyano-Almagro B, Contreras-Steyls M, Mendez-Abad C, et al. Efficacy and safety of adalimumab in patients with moderate to severe hidradenitis suppurativa. Our clinical experience [abstract no. 1628]. J Am Acad Dermatol. 2015;72(5 Suppl 1):AB208.","journal-title":"J Am Acad Dermatol."},{"key":"220_CR36","doi-asserted-by":"crossref","unstructured":"Consuegra G, Lacalle M, Vilanova I, et al. Biologic therapies for moderate to severe hidradenitis suppurativa [poster no. 3855]. In: 74th Annual Meeting of the American Academy of Dermatology; 2016.","DOI":"10.1016\/j.jaad.2016.02.181"},{"key":"220_CR37","doi-asserted-by":"crossref","unstructured":"Dini V, Oranges T, Rotella L, et al. TNF alpha inhibitors and hidradenitis suppurativa: our clinical experience [poster no. 3715]. In: 74th Annual Meeting of the American Academy of Dermatology; 2016.","DOI":"10.1016\/j.jaad.2016.02.037"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-016-0220-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40257-016-0220-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-016-0220-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T23:55:02Z","timestamp":1568418902000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40257-016-0220-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,24]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["220"],"URL":"https:\/\/doi.org\/10.1007\/s40257-016-0220-6","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,24]]}}}